212 related articles for article (PubMed ID: 31269600)
1. [IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].
Ji YC; Zhan YB; Liu XZ; Zhang ZY
Zhonghua Yi Xue Za Zhi; 2019 Jul; 99(25):1959-1962. PubMed ID: 31269600
[No Abstract] [Full Text] [Related]
2. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
3. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
[TBL] [Abstract][Full Text] [Related]
4. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
5. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
6. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
[TBL] [Abstract][Full Text] [Related]
7. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
8. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
Lee J; Putnam AR; Chesier SH; Banerjee A; Raffel C; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Perry A; Solomon DA
Acta Neuropathol Commun; 2018 Sep; 6(1):95. PubMed ID: 30231927
[No Abstract] [Full Text] [Related]
10. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
11. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
12.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
14. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
15. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
16. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
17. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract][Full Text] [Related]
18. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
[TBL] [Abstract][Full Text] [Related]
19. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V
Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823
[TBL] [Abstract][Full Text] [Related]
20. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]